Clinical Trial Update: To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SCD-044 for moderate to severe plaque psoriasis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SCD-044

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Moderate to Severe Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2026-01-20